Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) plus chemotherapy (chemo) +/- bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Socinski, Mark A.; Jotte, Robert M.; Cappuzzo, Federico; Orlandi, Francisco Jorquera; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodriguez-Abreu, Delvys; Moro-Sibilot, Denis; Thomas, Christian A.; Barlesi, Fabrice; Finley, Gene Grant; Kelsch, Claudia; Lee, Anthony; Coleman, Shelley; Shen, Yijing; Kowanetz, Marcin; Lopez-Chavez, Ariel; Sandler, Alan; Reck, Martin

authors

Publication Date

  • May 20, 2018

webpage

published in

category

volume

  • 36

issue

  • 15